Mainz. German drug maker, BioNTech announced yesterday that it has begun a trial of a malaria vaccine to examine the safety, tolerability and efficacy of the preparation called BNT165b1.
 |
| German pharmaceutical company BioNTech begans trial of a malaria vaccine to examine the safety, tolerability and efficacy of the preparation called BNT165b1. |
The company expects the phase 1 trial to include about 60 healthy participants with no previous or current malaria infection at various sites in the United States and said the vaccine candidate will be studied at three different dose levels.
"The start of this trial is an important milestone on our journey to contribute to the fight against diseases with high unmet medical needs," said BioNTech Chief Medical Officer and Co-Founder Özlem Türeci.
HOT🔥: León: Alleged Person Responsible For Running Over A Father And Son Released
He added that the goal is to develop an immunogen based on messenger ribonucleic acid (mRNA) technology that can help prevent malaria and reduce mortality.
The World Health Organization (WHO) estimates that some 619,000 people died of malaria worldwide in 2021, down slightly from about 625,000 deaths the previous year.
The report puts cases of the disease at 247 million, but the pace of increase has slowed. About 95 percent of illnesses and deaths were recorded in Africa. BioNTech, based in Mainz, western Germany, is building an mRNA vaccine production facility in Rwanda.
It is expected that the antigen against the coronavirus developed by BioNTech and its US partner Pfizer and potentially also mRNA vaccines against tuberculosis and malaria, for example, can be produced in the African country from 2024, if approved.
RELATED: Edomex. Man murders his sister and tells the whole family that she disappeared
So far, many children in Africa have already been inoculated with GlaxoSmithKline's RTS,S vaccine.
0 Comments: